Source link : https://newshealth.biz/health-news/b-cell-depleter-nabs-phase-iii-win-in-autoimmune-kidney-disease/
The B-cell depleting agent obinutuzumab (Gazyva) was superior to the immunosuppressant tacrolimus in inducing remissions in primary membranous nephropathy, the global phase III MAJESTY trial showed. By week 104, 37% of patients in the obinutuzumab group achieved complete remission — defined as a urinary protein-to-creatinine ratio of 0.3 or lower alongside a stable estimated glomerular […]
The post B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-05 16:55:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8